Медицинский совет (Dec 2014)

Effect of antihypertensive drugs on specific markers of inflammation and disorders of carbohydrate metabolism in metabolic syndrome

  • TE Morozova,
  • TB Andruschishina,
  • ER Kuzmina

DOI
https://doi.org/10.21518/2079-701X-2014-12-100-105
Journal volume & issue
Vol. 0, no. 12
pp. 100 – 105

Abstract

Read online

The potential of certain drugs to affect specific markers of progression of hypertension should be taken into account in the rational pharmacotherapy of arterial hypertension (AH) in patients with metabolic syndrome (MS). Pharmacodynamic effects of the beta-blocker (BB) nebivolol, the average daily dose 5,3 ± 2,5 mg, were studied in 29 patients with stage I - II hypertension with signs of MS (men - 15, women - 14; mean age 52, 4 ± 10,32 years). Nebivolol, along with a high antihypertensive efficacy (achievement of target blood pressure in 76% of patients) and good safety profile, provides a complex effect on specific markers of inflammation and disorders of carbohydrate metabolism. The study showed a decrease in the high-sensitivity C-reactive protein (hs-CRP) from 3.15 (2.0; 4.18) mg/l to 2.3 (1.18; 4.03) mg/l (p = 0.001), intercellular adhesion molecules (iCAM-1) from 330,23 (295.7; 387.3) ng/ml to 310.07 (252.72; 370.4) ng/ml (p = 0.044) with no adverse effect on insulin resistance, as well as a reduction in the adipokine activity and overall cardiovascular risk.

Keywords